Literature DB >> 18838594

Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.

Lauren Becnel Boyd1, Merry J Maynard, Sonia K Morgan-Linnell, Lori Banks Horton, Richard Sucgang, Richard J Hamill, Javier Rojo Jimenez, James Versalovic, David Steffen, Lynn Zechiedrich.   

Abstract

Fluoroquinolones are some of the most prescribed antibiotics in the United States. Previously, we and others showed that the fluoroquinolones exhibit a class effect with regard to the CLSI-established breakpoints for resistance, such that decreased susceptibility (i.e., an increased MIC) to one fluoroquinolone means a simultaneously decreased susceptibility to all. For defined strains, however, clear differences exist in the pharmacodynamic properties of each fluoroquinolone and the extent to which resistance-associated genotypes affect the MICs of each fluoroquinolone. In a pilot study of 920 clinical Escherichia coli isolates, we uncovered tremendous variation in norfloxacin MICs. The MICs for all of the fluoroquinolone-resistant isolates exceeded the resistance breakpoint, reaching 1,000 microg/ml. Approximately 25% of the isolates (n = 214), representing the full range of resistant norfloxacin MICs, were selected for the simultaneous determinations of ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs. We found that (i) great MIC variation existed for all four fluoroquinolones, (ii) the ciprofloxacin and levofloxacin MICs of >90% of the fluoroquinolone-resistant isolates were higher than the resistance breakpoints, (iii) ciprofloxacin and levofloxacin MICs were distributed into two distinct groups, (iv) the MICs of two drug pairs (ciprofloxacin and norfloxacin by Kendall's Tau-b test and gatifloxacin and levofloxacin by paired t test) were similar with statistical significance but were different from each other, and (v) approximately 2% of isolates had unprecedented fluoroquinolone MIC relationships. Thus, although the fluoroquinolones can be considered equivalent with regard to clinical susceptibility or resistance, fluoroquinolone MICs differ dramatically for fluoroquinolone-resistant clinical isolates, likely because of differences in drug structure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18838594      PMCID: PMC2612140          DOI: 10.1128/AAC.00722-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

Review 1.  Quinolone-mediated bacterial death.

Authors:  Karl Drlica; Muhammad Malik; Robert J Kerns; Xilin Zhao
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

2.  Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118.

Authors:  A Dalhoff
Journal:  Clin Infect Dis       Date:  2001-03-15       Impact factor: 9.079

3.  Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus.

Authors:  T Lu; X Zhao; X Li; A Drlica-Wagner; J Y Wang; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 4.  Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.

Authors:  X Zhao; K Drlica
Journal:  Clin Infect Dis       Date:  2001-09-15       Impact factor: 9.079

5.  Relative contributions of the AcrAB, MdfA and NorE efflux pumps to quinolone resistance in Escherichia coli.

Authors:  Shirley Yang; Sonia Rahmati Clayton; E Lynn Zechiedrich
Journal:  J Antimicrob Chemother       Date:  2003-03       Impact factor: 5.790

6.  Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates.

Authors:  Sonia K Morgan-Linnell; Lauren Becnel Boyd; David Steffen; Lynn Zechiedrich
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

7.  Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China.

Authors:  Minggui Wang; John H Tran; George A Jacoby; Yingyuan Zhang; Fu Wang; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

8.  Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.

Authors:  Sonia K Morgan-Linnell; Lynn Zechiedrich
Journal:  Antimicrob Agents Chemother       Date:  2007-08-06       Impact factor: 5.191

9.  Dose-related selection of fluoroquinolone-resistant Escherichia coli.

Authors:  Sara K Olofsson; Linda L Marcusson; Ann Strömbäck; Diarmaid Hughes; Otto Cars
Journal:  J Antimicrob Chemother       Date:  2007-07-16       Impact factor: 5.790

10.  Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location.

Authors:  Lauren Becnel Boyd; Robert L Atmar; Graham L Randall; Richard J Hamill; David Steffen; Lynn Zechiedrich
Journal:  BMC Infect Dis       Date:  2008-01-15       Impact factor: 3.090

View more
  27 in total

1.  Expression of multidrug efflux pump genes acrAB-tolC, mdfA, and norE in Escherichia coli clinical isolates as a function of fluoroquinolone and multidrug resistance.

Authors:  Michelle C Swick; Sonia K Morgan-Linnell; Kimberly M Carlson; Lynn Zechiedrich
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

2.  De Novo Characterization of Genes That Contribute to High-Level Ciprofloxacin Resistance in Escherichia coli.

Authors:  Thu Tran; Qinghong Ran; Lev Ostrer; Arkady Khodursky
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

3.  Magainin 2 induces bacterial cell death showing apoptotic properties.

Authors:  Wonyoung Lee; Dong Gun Lee
Journal:  Curr Microbiol       Date:  2014-07-15       Impact factor: 2.188

Review 4.  Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria.

Authors:  Hiroshi Nikaido; Jean-Marie Pagès
Journal:  FEMS Microbiol Rev       Date:  2011-07-29       Impact factor: 16.408

5.  DprB facilitates inter- and intragenomic recombination in Helicobacter pylori.

Authors:  Xue-Song Zhang; Martin J Blaser
Journal:  J Bacteriol       Date:  2012-05-18       Impact factor: 3.490

6.  Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis.

Authors:  Michael A Kohanski; Mark A DePristo; James J Collins
Journal:  Mol Cell       Date:  2010-02-12       Impact factor: 17.970

7.  Incidence rate of fluoroquinolone-resistant gram-negative rod bacteremia among allogeneic hematopoietic cell transplantation patients during an era of levofloxacin prophylaxis.

Authors:  Arianna Miles-Jay; Susan Butler-Wu; Ali Rowhani-Rahbar; Steven A Pergam
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-11       Impact factor: 5.742

8.  Evaluation of quinolones for use in detection of determinants of acquired quinolone resistance, including the new transmissible resistance mechanisms qnrA, qnrB, qnrS, and aac(6')Ib-cr, in Escherichia coli and Salmonella enterica and determinations of wild-type distributions.

Authors:  L M Cavaco; F M Aarestrup
Journal:  J Clin Microbiol       Date:  2009-07-01       Impact factor: 5.948

9.  Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates.

Authors:  Sonia K Morgan-Linnell; Lauren Becnel Boyd; David Steffen; Lynn Zechiedrich
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

10.  Rapid Detection of Genomic Mutations in gyrA and parC Genes of Escherichia coli by Multiplex Allele Specific Polymerase Chain Reaction.

Authors:  Sukanlayanee Onseedaeng; Panan Ratthawongjirakul
Journal:  J Clin Lab Anal       Date:  2016-04-13       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.